TrialHealth technology assessment (Winchester, England)2020

Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.

Helena Earl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.